Total Payments
$1.2M
2024 Payments
$152,898
Companies
90
Transactions
3,221
Medicare Patients
3,009
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$959,716 (77.3%)
Consulting$169,237 (13.6%)
Food & Beverage$56,919 (4.6%)
Travel$55,761 (4.5%)
Education$332.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $952,576 | 382 | 76.7% |
| Consulting Fee | $169,237 | 79 | 13.6% |
| Food and Beverage | $56,919 | 2,287 | 4.6% |
| Travel and Lodging | $55,761 | 458 | 4.5% |
| Honoraria | $7,140 | 6 | 0.6% |
| Education | $332.46 | 9 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $451,191 | 556 | $0 (2022) |
| ABBVIE INC. | $415,367 | 609 | $0 (2024) |
| Amgen Inc. | $140,522 | 275 | $0 (2023) |
| Biohaven Pharmaceuticals, Inc. | $72,725 | 128 | $0 (2021) |
| IMPEL PHARMACEUTICALS INC. | $32,442 | 41 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $24,845 | 179 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $20,088 | 63 | $0 (2021) |
| PFIZER INC. | $20,073 | 66 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $16,274 | 49 | $0 (2022) |
| Lundbeck LLC | $11,829 | 83 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152,898 | 307 | ABBVIE INC. ($143,922) |
| 2023 | $164,931 | 361 | AbbVie Inc. ($135,177) |
| 2022 | $169,561 | 377 | ABBVIE INC. ($90,488) |
| 2021 | $271,170 | 494 | Allergan, Inc. ($140,688) |
| 2020 | $184,256 | 406 | Allergan, Inc. ($155,285) |
| 2019 | $130,366 | 479 | Amgen Inc. ($61,448) |
| 2018 | $95,867 | 394 | Amgen Inc. ($37,712) |
| 2017 | $72,916 | 403 | Allergan Inc. ($42,068) |
All Payment Transactions
3,221 individual payment records from CMS Open Payments — Page 1 of 129
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/20/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Analgesic | ||||||
| 12/18/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: EPILEPSY | ||||||
| 12/17/2024 | ABBVIE INC. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/17/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Cycle Pharmaceuticals Inc | Ormalvi (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $10.99 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $8.90 | General |
| Category: PAIN | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $8.35 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $5.20 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $43.28 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $10.29 | General |
| Category: Analgesic | ||||||
| 12/10/2024 | ABBVIE INC. | QULIPTA (Drug) | Travel and Lodging | In-kind items and services | $5.20 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $33.11 | General |
| Category: Neuropsychiatry | ||||||
| 12/02/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 11/27/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.78 | General |
| Category: NEUROLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: PAIN | ||||||
| 11/21/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 738 | 61,492 | $1.0M | $381,559 |
| 2022 | 19 | 871 | 60,794 | $1.1M | $381,474 |
| 2021 | 18 | 709 | 61,895 | $1.1M | $388,552 |
| 2020 | 18 | 691 | 54,975 | $996,897 | $344,129 |
Total Patients
3,009
Total Services
239,156
Medicare Billing
$1.5M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 3 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 14 | 14 | $15,400 | $2,050 | 13.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $3,652 | $1,767 | 48.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 77 | 53,500 | $535,000 | $253,589 | 47.4% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 46 | 154 | $123,200 | $16,768 | 13.6% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2020 | 69 | 502 | $20,080 | $13,853 | 69.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 67 | 90 | $49,500 | $6,881 | 13.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 53 | 163 | $36,675 | $5,504 | 15.0% |
| 64612 | Injection of chemical for destruction of nerve muscles on one side of face | Office | 2020 | 11 | 35 | $12,775 | $5,315 | 41.6% |
| 64644 | Injection of chemical for destruction of nerve muscles on arm or leg, 5 or more muscles | Office | 2020 | 11 | 37 | $11,100 | $5,143 | 46.3% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2020 | 26 | 81 | $6,075 | $4,734 | 77.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 55 | 88 | $26,400 | $4,672 | 17.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 38 | 38 | $22,800 | $4,645 | 20.4% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2020 | 31 | 52 | $20,800 | $4,264 | 20.5% |
| 95939 | Insertion of needles and skin electrodes for measurement and recording of stimulated sites in the arms and legs | Facility | 2020 | 37 | 38 | $26,448 | $3,816 | 14.4% |
| 95913 | Nerve transmission studies, 13 or more studies | Office | 2020 | 15 | 15 | $26,250 | $3,755 | 14.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 17 | $5,644 | $2,845 | 50.4% |
| 95938 | Insertion of needles and skin electrodes for measurement and recording of stimulated sites in the arms and legs | Facility | 2020 | 65 | 67 | $39,798 | $2,597 | 6.5% |
| 95861 | Needle measurement and recording of electrical activity of muscles of arms or legs | Facility | 2020 | 35 | 36 | $8,928 | $2,498 | 28.0% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2020 | 12 | 12 | $13,200 | $1,941 | 14.7% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Facility | 2020 | 12 | 23 | $9,200 | $890.28 | 9.7% |
| 95885 | Needle measurement and recording of electrical activity of muscles of arm or leg limited study | Facility | 2020 | 14 | 27 | $3,024 | $417.60 | 13.8% |
About Dr. Ravi Shah, MD
Dr. Ravi Shah, MD is a Neurology healthcare provider based in Parker, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013999895.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ravi Shah, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $152,898 received in 2024. These payments were reported across 3,221 transactions from 90 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($952,576).
As a Medicare-enrolled provider, Shah has provided services to 3,009 Medicare beneficiaries, totaling 239,156 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Parker, CO
- Active Since 11/16/2005
- Last Updated 05/06/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013999895
Products in Payments
- BOTOX (Biological) $464,302
- UBRELVY (Drug) $222,023
- Aimovig (Biological) $120,067
- NURTEC ODT (Drug) $108,631
- QULIPTA (Drug) $75,215
- BOTOX (Drug) $55,537
- Trudhesa (Drug) $32,442
- BOTOX CHRONIC MIGRAINE (Drug) $21,314
- ONZETRA Xsail (Drug) $18,167
- AJOVY (Drug) $14,218
- VYEPTI (Biological) $11,328
- AJOVY (Biological) $9,686
- Cambia (Drug) $5,951
- BOTOX - MIGRAINE (Drug) $5,762
- TREXIMET (Drug) $5,050
- TROKENDI XR (Drug) $4,129
- Zembrace (Drug) $2,028
- ZEMBRACE SYMTOUCH (Drug) $1,635
- NUEDEXTA (Drug) $1,166
- ONZETRA (Drug) $770.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.